Kellerhals Carrard has advised Ypsomed Holding on CHF 122.5 million capital increase and listing of 1’000’000 new shares on SIX Swiss Exchange. The new registered shares were successfully listed. Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowed diabetes specialist. Zürcher Kantonalbank acted as Sole Global Coordinator of this capital increase. The first trading day of the new registered shares was 28 June 2022.
Kellerhals Carrard advised Ypsomed and Zürcher Kantonalbank as Counsel to the Transaction on the capital increase and listing. The team was led by partner Beat Brechbühl (capital markets, pictured left), Frédéric Rochat (partner, capital markets, pictured right), Luca Bianchi (partner, capital markets), Reto Schumacher (partner, corporate), Jörg von Manger-König (Of Counsel, life sciences), Philippe Frésard (partner, notary), Robin Juchle r(associate, capital markets) and Christian Witschi (partner, tax).